ClinicalTrials.gg

Program

GTX-B001

A development code.

Its studies are mostly in Urticaria, led by Granular Therapeutics.

Furthest: phase 1, since Sep 12, 20251 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Granular Therapeutics11 open or runningphase 1since Sep 12, 2025Sep 12, 2025Aug 2027phase 1 · NCT07181369

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2025First study: phase 1 study in Cold UrticariaFirst studyNCT07181369 · 72 planned · Germany

Ahead

  1. Aug 2027Primary completion: phase 1 study in Cold UrticariaNCT07181369

TargetBeta

ENPP3 →read by rule
“GTX-B001 is a humanized bispecific antibody than binds with one arm to a protein called c-Kit and with the second arm to a protein called CD203c, both expressed on mast cells.”study text, by rule · the study

Other programs on ENPP3

ProgramCompanyFurthest phaseStudies
Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387Johnson & Johnsonphase 11
JNJ-89862175Johnson & Johnsonphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07181369Cold Urticaria · Germany1RecruitingAug 202772

How it is read

Names in the registry

  • “GTX-B001”, 1 entry

Codes read as this program: ALY301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.